Aprepitant clinical trials
Also written Emend, MK-0869 and ONO-7436.
Counted the way a researcher would: Aprepitant with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Aprepitant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Aprepitant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Mar 2003 · EMEND · NDA 021549 (FDA, Drugs@FDA)
- European Union
- 11 Nov 2003 · Emend · EMEA/H/C/000527 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
127 studies that test it; most in 2011 (13)
| Year | Studies |
|---|---|
| 2001 | 5 |
| 2002 | 4 |
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 9 |
| 2008 | 7 |
| 2009 | 9 |
| 2010 | 8 |
| 2011 | 13 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 9 |
| 2015 | 8 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 103
Merck Sharp & Dohme LLC (19) · Sun Yat-sen University (4) · University of Pennsylvania (4) · The Hospital for Sick Children (2) · Vanderbilt University (2) · NYU Langone Health (2) · Mayo Clinic (2) · Dartmouth-Hitchcock Medical Center (2)
Often tested with
Tested in the same studies.
Dexamethasone (19) · Ondansetron (13) · Fosaprepitant (8) · Palonosetron (7) · Granisetron (5) · Olanzapine (3) · Ramosetron (3) · Cyclophosphamide (2)
Related medicines
As reviewed, each with the page that says it.
- One of Antiemetics source
- One of NK1 receptor antagonists source
- Fosaprepitant is a prodrug of it, counted here with related medicines source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test Aprepitant.
- Mar 2027Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis SurgeryPhase 2 · IWK Health Centre
- May 2027Aprepitant for the Treatment of CLIFAHDDEarly Phase 1 · The University of Texas Health Science Center at San Antonio
- Jun 2027Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic SurgeryPhase 4 · Sir Mortimer B. Davis - Jewish General Hospital
- Jul 2027Aprepitant to Improve Same Day Discharge for TKAPhase 4 · Endeavor Health
Studies
Open first, then newest update. How each study uses Aprepitant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 128
- Aprepitant for the Treatment of CLIFAHDDRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT07845825Written as Aprepitant Powder for Oral Suspension
- Aprepitant to Improve Same Day Discharge for TKANot yet recruitingPhase 4Endeavor HealthNCT07639723Written as Aprepitant Injection
- Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis SurgeryRecruitingPhase 2IWK Health CentreNCT06357234Written as Aprepitant
- Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic SurgeryNot yet recruitingPhase 4Sir Mortimer B. Davis - Jewish General HospitalNCT07371728Written as Aprepitant
- Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer PatientsNot yet recruitingPhase 1Rabin Medical CenterNCT06931119Written as EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd.
- Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and VomitingNot yet recruitingPhase 3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT06543966Written as Aprepitant Injection
- Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCCNot yet recruitingPhase 3Guangxi Medical UniversityNCT05711823Written as Aprepitant in combination with granisetron and dexamethasone
- Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerNot yet recruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05841849Written as Aprepitant
- Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical PatientsCompletedPhase 3Centre hospitalier de l'Université de Montréal (CHUM)NCT07248280Written as Aprepitant 40mg
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated DataCompletedPhase 3Jennifer Holder-MurrayNCT04606264Written as Aprepitant
- Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor PatientsCompletedPhase 3Sichuan Cancer Hospital and Research InstituteNCT06007586Written as Aprepitant Injection
- Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative NeoplasmsCompletedPhase 3University Hospital, BrestNCT03808805Written as Aprepitant 80 mg
- Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and VomitingCompletedPhase 3Qilu Pharmaceutical (Hainan) Co., Ltd.NCT06932107Written as Aprepitant Injection
- Topical Aprepitant in Prurigo PatientsCompletedPhase 2LEO PharmaNCT01963793Written as Aprepitant
- Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.TerminatedPhase 4Insel Gruppe AG, University Hospital BernNCT05189756Written as Aprepitant 80 mg
- Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary DysmenorrheaCompletedPhase 3Lahore Medical Research Center, LLPNCT06317064Written as Ibuprofen and Aprepitant
- Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid CancerCompletedPhase 4The First Affiliated Hospital of Zhengzhou UniversityNCT06697782Written as Aprepitant 125 mg
- Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast CancerCompletedPhase 1UNC Lineberger Comprehensive Cancer CenterNCT00719173Written as aprepitant
- Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose MelphalanCompletedPhase 3Rush University Medical CenterNCT02939287Written as Aprepitant plus Olanzapine
- Comparison of Adding EMEND to PONV/PDNV Treatment RegimenWithdrawnNot applicableUniversity of NebraskaNCT01186029Written as aprepitant
See all 128 studies that test Aprepitant →
Given beside what is tested · 16 — Aprepitant is usual care or a partner of the new treatment
- Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 BlockadeRecruitingNot applicableHubei Cancer HospitalNCT06080880Written as Aprepitant
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3CompletedPhase 4Yale UniversityNCT04649229Written as Aprepitant
- Phase 2 Bunionectomy HTX-011 Administration StudyCompletedPhase 2Heron TherapeuticsNCT03718039Written as aprepitant
- Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and AdolescentsStatus unknownPhase 3Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT05346731Written as Aprepitant
- A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent GlioblastomaCompletedPhase 1/2University of UlmNCT02770378Written as Aprepitant
- Granisetron Transdermal Patch for Prophylaxis of Delayed CINVStatus unknownPhase 3Fudan UniversityNCT04912271Written as Aprepitant
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"CompletedPhase 3All India Institute of Medical Sciences, New DelhiNCT03219710Written as Aprepitant
- Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)CompletedPhase 1Merck Sharp & Dohme LLCNCT00871910Written as Aprepitant
- Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus AprepitantCompletedNot applicableKyungpook National University HospitalNCT02597907Written as aprepitant
- Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and VomitingCompletedPhase 3First Affiliated Hospital of Harbin Medical UniversityNCT02484911Written as Aprepitant
- Ondansetron Versus Aprepitant Plus Ondansetron for EmesisCompletedPhase 2M.D. Anderson Cancer CenterNCT00954941Written as Aprepitant
- Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)CompletedPhase 1Merck Sharp & Dohme LLCNCT01111851Written as Aprepitant 165 mg
- Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)CompletedNot applicableOhio State University Comprehensive Cancer CenterNCT01640340Written as aprepitant
- Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/CarboplatinCompletedPhase 2Samsung Medical CenterNCT01012336Written as Aprepitant/Ramosetron/Dexamethasone
- Aprepitant in the Management of Biological Therapies-related Severe PruritusCompletedPhase 2Campus Bio-Medico UniversityNCT01683552Written as Aprepitant
- Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic SurgeriesStatus unknownNot applicableMain Line HealthNCT00835965Written as Aprepitant
As the comparator · 8 — what is tested is compared with Aprepitant
- QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous AdministrationNot yet recruitingPhase 1Qilu Pharmaceutical (Hainan) Co., Ltd.NCT07817004Written as apripitant injection (CINVANTI)
- A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving ChemotherapyNot yet recruitingEarly Phase 1Ottawa Hospital Research InstituteNCT07662200Written as Aprepitant
- Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapyCompletedPhase 3CR-CSSS Champlain-Charles-Le MoyneNCT04075955Written as Emend® (Aprepitant)
- Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic ChemotherapyStatus unknownPhase 3Mahidol UniversityNCT03876938Written as aprepitant
- Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent NauseaCompletedPhase 4Loyola UniversityNCT00781768Written as Aprepitant (MK-869) + Standard PO
- Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)CompletedPhase 3Merck Sharp & Dohme LLCNCT00619359Written as Comparator: Aprepitant
- Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical TrialCompletedPhase 3Joseph RoscoeNCT00475085Written as aprepitant
- A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingCompletedPhase 3Helsinn Healthcare SANCT01376297Written as Aprepitant
Codes
What other systems call Aprepitant · ClinicalTrials.gg INT006778
- MeSH (NLM) D000077608AprepitantConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1NF15YR6UYAPREPITANTConfirmed FDA, NLM, Wikidata
- RxNorm 358255Confirmed FDA, Wikidata
- Wikidata Q621834aprepitantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49173AprepitantOne source FDA
- DrugBank DB00673One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077608 | Aprepitant | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1NF15YR6UY | APREPITANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 358255 | — | Confirmed FDA, Wikidata |
| Wikidata | Q621834 | aprepitant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49173 | Aprepitant | One source FDA |
| DrugBank | DB00673 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.